

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1348

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/005,996
Filing Date	December 3, 2001
First Named Inventor	William M. Partridg
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	407T-994110US
Date Submitted	November 11, 2003

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
8W	01	BOADO et al. (1998) "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS." J. Pharm. Sci. 87:1308-1315.	

Examiner Signature		Date Considered	10/19/04
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
AUG 26 2002  
TECH CENTER 1800/2000

Substitute for form 1449A-B/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use as many sheets as necessary)


OIP  
AUG 23 2002  
PATENT & TRADEMARK OFFICE

Complete if Known  
Application Number 10/005,996  
Filing Date December 3, 2001  
First Named Inventor William M. Partridge  
Group Art Unit 1645  
Examiner Name Unassigned  
Attorney Docket Number 407T-994110US  
Date Submitted

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	01	4,801,575		Pardridge	01-31-1989	
	02	4,902,505		Pardridge et al.	02-20-1990	
	03	6,287,792	B1	Pardridge et al.	09-11-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JK	04	EP	0 592 564	B1				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
JK	05	Agrawal et al. (1991) Proc. Natl. Acad. Sci., USA, 88:7595-7599.			
JK	06	Boado and Pardridge (1994) Bioconj. Chem., 6: 406-410			
JK	07	Boado and Pardridge (1998) Mol. Brain Res. 59: 109-113.			
JK	08	Boado et al. (1999) Proc. Natl. Acad. Sci., USA, 96: 12079-12084.			
JK	09	Boado et al. (2000) J. Pharmacol. Exp. Ther., 295: 239-243.			
JK	10	Brown et al. (1994) J. Biol. Chem., 269:26801-26805.			
JK	11	Chen et al. (1990) Drug Metab. Dispos. 18:518-818. CHEN ET AL.			
JK	12	Chinnery et al. (1999) Gene Ther. 6: 1919-1928.			
JK	13	Coloma et al. (2000) Pharm. Res. 17:266-274.			
	14	Cossum et al. (1993) J. Pharmacol. Exp. Ther., 267: 1181-1190.			
	15	Crookie (1993) FASEB J. 7:533-539.			
	16	de Smidt et al. (1991) Nucleic Acids Res. 19: 4695-4700.			
	17	Demidov et al. (1994) Biochem. Pharmacol. 48: 1310-1313.			
JK	18	Gee et al. (1998) Antisense and Nucleic Acid Drug Develop. 8:103-111.			


Examiner Signature  Date Considered 10/19/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (as many sheets as necessary)	Complete if Known	
	Application Number	10/005,996
	Filing Date	December 3, 2001
	First Named Inventor	William M. Partridge
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	407T-994110US
Date Submitted		

RECEIVED  
AUG 26 2002  
TECH CENTER 1800/2900

19	Harvey et al. (1992) Science., 258:1481-1486.	
20	Heffetz et al. (1989) Eur. J. Biochem. 182:343-348.	
21	Hnatowich (1999) J. Nucleic Med. 40: 693-703.	
22	Huwyler and Pardridge (1998) J. Neurochem. 70:883-886.	
23	Kang et al.(1995) Drug Metab. Dispos. 23: 55-59.	
24	<del>Krupa et al.</del> (1999) Phil. Trans. R. Soc. Lond., 354: 963-969. SATHASIVAM ET AL.	
25	Kobori et al. (1999) NeuroReport 10: 2971-2974.	
26	Krieg et al. (1993) Proc. Natl. Acad. Sci., USA, 90: 1048-1052.	
27	Kurihara and Pardridge (1999) Cancer Res. 54: 6159-6163.	
28	Kurihara et al. (1999) Bioconjugate Chem. 10: 502-511.	
29	Lee et al. (2000) J. Pharmacol. Exp Ther. 292:1048-1052.	
30	Li et al. (1999) Protein Engineering 12:787-796.	
31	Lockhart and Winzeler (2000) Nature., 405: 827-836	
32	Mash et al. (1990) J. Neurochem. 55: 1972-1979.	
33	Mayfield and Corey (1999) Anal. Biochem., 268: 401-404.	
34	Nielsen et al. (1994) Bioconjugate Chem. 5: 3-7.	
35	Pardridge (2001) Drug Discovery Today., 6: 104-106	
36	Pardridge (1997) J. Cereb. Blood Flow Metabol. 17:713-731.	
37	Pardridge et al. (1995) Pharm. Res. 12:807-816.	
38	Pardridge et al. (1995)Proc. Natl. Acad. Sci., USA, 92:5592-5596.	
39	Penichet et al. (1999) J. Immunol. 163:4421-4426.	
40	Rebert et al. (1990) Pharmacol. Biochem. Behav. 36: 351-356.	
41	Rockwell et al. (1997)Proc. Natl. Acad. Sci., USA, 94:6523-6528.	
42	Samii et al. (1994) Am. J. Physiol., 267: E124-E134.	
43	Shechter et al. (1982) Nature 216:542-545.	
44	Shi and Pardridge (2000) Proc. Natl. Acad. Sci., USA, 97, 7567-7572.	
45	Shi et al. (2000) Proc. Natl. Acad. Sci., USA, 97: 14709-14714.	
46	Skarlatos et al. (1995) Brain Res., 683: 164-171	

Examiner Signature		Date Considered	10/19/04
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/005,996
	Filing Date	December 3, 2001
	First Named Inventor	William M. Partridge
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	407T-994110US
Date Submitted		

TECH CENTER 1600/2900

AUG 26 2002

RECEIVED

<i>tu</i>	47	Stein and Cheng (1993) Science 261:1004-1012.	
<i>tu</i>	48	Tavitian et al. (21998) Nat. Med., 4: 467-471	
<i>tu</i>	49	Tsukamoto et al. (1997) J. Neurochem. 68: 2587-2592.	
<i>tu</i>	50	Tyler et al. (1999) Proc. Natl. Acad. Sci., USA, 96: 7053-7058.	
<i>tu</i>	51	Ueda et al. (1993) J. Neurochem. 60: 106-113.	
<i>tu</i>	52	Whitesell et al. (1993) Proc. Natl. Acad. Sci., USA, 90: 4665-4669.	
<i>tu</i>	53	Wickstrom (1986) J. Biochem. Biophys. Methods 13:97-102.	
<i>tu</i>	54	Wittung et al. (1994) Nature 368:561-563.	
<i>tu</i>	55	Wojcik et al. (1996) J. Pharmacol. Exp. Ther. 278:404-410.	
<i>tu</i>	56	Wu et al. (1996) J. Pharmacol. Exp. Ther., 276: 206-211.	
<i>tu</i>	57	Zendegui et al. (1992) Nucleic Acids Res. 20:307-314.	
<i>tu</i>	58	Zhang and Pardridge (2001) J. Neurochem., 76: 1597-1600.	
<i>tu</i>	59	Zhao et al. (1999) J. Biol. Chem. 274: 34893-34902.	
<i>tu</i>	60	Zick et al. (1984) J. Biol. Chem. 259:4396-4400.	

Examiner Signature		Date Considered	10/19/04
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.